Drug Trial Radar · NCT02720094
Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men
Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,570
Actual
Start
Dec 19, 2016
Primary completion
May 14, 2020
Study completion Mar 31, 2025
Sponsor
- Sponsor type
- NIH
- Collaborators
- ViiV Healthcare; Gilead Sciences
- First posted
- Mar 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Conditions
- HIV Infections
Interventions
Cabotegravir Oral TabletDrug
30 mg tablet
TDF/FTC tabletsDrug
300 mg/200 mg fixed-dose combination tablets
Placebo for TDF/FTC tabletsDrug
Placebo for cabotegravir oral tabletDrug
CAB LADrug
Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Placebo for CAB LADrug
Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Documented Incident HIV Infections During Steps 1 and 2Time frame: HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.
- Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse EventsTime frame: Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).
Locations
43 sites in 7 countries. Site status is shown where the registry gives one.
Alabama CRS
Birmingham, Alabama
UCLA Vine Street Clinic CRS
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
East Bay AIDS Center (EBAC) CRS
Oakland, California
Bridge HIV CRS
San Francisco, California
Children's Hospital Colorado CRS
Aurora, Colorado
George Washington Univ. CRS
Washington D.C., District of Columbia
The Ponce de Leon Center CRS
Atlanta, Georgia
The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia
Adolescent & Young Adult Research at The CORE Center (AYAR at CORE)
Chicago, Illinois
UIC Project WISH CRS
Chicago, Illinois
New Orleans Adolescent Trials Unit CRS
New Orleans, Louisiana
Johns Hopkins University CRS
Baltimore, Maryland
Fenway Health (FH) CRS
Boston, Massachusetts
Washington University Therapeutics (WT) CRS
St Louis, Missouri
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey
Weill Cornell Chelsea CRS
New York, New York
Harlem Prevention Center CRS
New York, New York
New York Blood Center CRS
New York, New York
Bronx Prevention Research Center CRS
The Bronx, New York
Chapel Hill CRS
Chapel Hill, North Carolina
Greensboro CRS
Greensboro, North Carolina
Cincinnati Clinical Research Site
Cincinnati, Ohio
Ohio State University CRS
Columbus, Ohio
Penn Prevention CRS
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital CRS
Memphis, Tennessee
Houston AIDS Research Team CRS
Houston, Texas
Fundacion Huesped CRS
Buenos Aires, Argentina
Hospital General de Agudos JM Ramos Mejía CRS
Ciudad de Buenos Aires, Buenos Aires, Argentina
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
Rio de Janeiro, Brazil
Centro de Pesquisas Clínicas IC-HCFMUSP CRS
São Paulo, Brazil
Hospital Nossa Senhora da Conceicao CRS
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Referencia e Treinamento DST/AIDS CRS
São Paulo, São Paulo, Brazil
Via Libre CRS
Lima, Peru
Barranco CRS
Lima, Peru
San Miguel CRS
Lima, Peru
ACSA CRS
Iquitos, Maynas, Peru
CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS
Bellavista, Provincia Constitucional del Callao, Peru
Groote Schuur HIV CRS
Cape Town, Western Cape, South Africa
CMU HIV Prevention CRS
Chiang Mai, Thailand
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.